

# COVID-19 Vaccine Strategy

New Zealand

*Dr Michael Tatley*

*Associate Professor*

*University of Otago/New Zealand Pharmacovigilance Centre*



Te Whare Wānanga o Ōtago



# Caveats

## I am not a New Zealand Government Official

- New Zealand COVID-19 Strategy position references and vaccination details are extracted from publically available sources.
- The New Zealand COVID-19 Vaccine Safety Surveillance Strategy presented is a Framework proposal that is partly implemented.

This presentation reflects observations from The NZ Pharmacovigilance Centre at the University of Otago.



# Outline

- New Zealand COVID-19 Vaccine initiatives
- Proposal for COVID-19 Vaccine Safety Strategy for the Pacific
- IMSN role in ME analysis?



# New Zealand's COVID-19 Vaccine Strategy

## Outcomes

- Supply of safe & effective COVID-19 vaccine
- Protect Maori, Pacific & other at risk population groups
- Full Cultural, Social, Economic recovery from COVID-19 Impacts
- NZ as a valued contributor to global wellbeing and the COVID-19 response
- NZ, Pacific & Global preparedness to respond to future disease outbreaks

## Work strands

- Global connection & contribution (vaccine development, distribution, use)
- Invest in research – global contribution, builds relationships, supports early vaccine access
- Develop manufacturing ability (in case needed)
- Optimise regulatory approaches (ensure quality/safety, support research, enable manufacture)
- Use purchasing arrangements to secure supply & enhance resilience.

Support WHO in equitable COVID-19 Vaccine distribution globally

**Includes focus in ensuring vaccine access for our Pacific Island partners**



# New Zealand's COVID-19 Vaccine Strategy

## *operational*

### Funding allocated to

- Domestic research
- Manufacturing capability
- International Research Collaboration
- GAVI assistance

### Organisational


- COVID-19 Strategy Group
- COVID-19 Vaccine Strategy Task Force
- Scientific and Technical Advisory Group
- COVID-19 Vaccine Implementation Task Force

*COVID Vaccine Pillars*

***POST EVENT PILLAR***



# NZ COVID-19 Vaccine Safety Surveillance Strategy



# COVID-19 Vaccine Monitoring in New Zealand

## *Passive Monitoring*



- CIR Adverse Event Module (20 minute observation window)
- CARM COVID-19 Online Reporting (outside vaccination site)

- Standardized approach
- Rapid Easy entry
- Tickboxes

## CARM traditional



- Online
- PMS software
- Hardcopy Reporting Card
- Email
- Telephone



# What happens to reports of AEFI's to CARM?

- **Triaged**

Serious

Critical terms or events

Hospitalization  
Life threatening  
Death  
Medically significant  
Persisting disability  
Congenital abnormality

Anaphylaxis  
Neurological event  
Bleeding clotting event  
Adverse Event of Special Interest

- Additional events added/data consistency check/'causality'

- Seek further information to clarify event reported

- **Identify events of concern**

AESI's

Patterns of events raising concern

Unexpected events or Signals

**Independent Safety Monitoring Board**

*Review Events of concern*


*Review Safety data locally/globally*

*Identify Vaccine Safety issues and risks to CVIP & Medsafe*





# CARM COVID AEFI Workflow




# Cumulative and Planned vaccination doses in New Zealand Pfizer Vaccine

Dose 1	172 564
Dose 2	60 024
<b>TOTAL</b>	<b>232 588</b>

27 April 2021

## Cumulative planned and projected doses to December 2021



Source : NZ Ministry of Health

# Adverse events following Immunisation in New Zealand Pfizer Vaccine

AEFI reports received and vaccine doses administered, up to and including 27 March 2021



# COVID-19 Medication Error

## Principle

- CARM to receive reports resulting in HARM (i.e. reaches the patient)
- “Programme” manages

no Harm  
near miss

Cold chain  
Quality  
Dilution

= Immediate response by Operational Programme

## Reporting options

AEFI  
AEFI + Error (harm) **CARM**

Error  
no injury, but reaches patient  
no injury  
Immunization Programme

### EVENTS

<i>Wrong site</i>	<i>4</i>
<i>Needle stick</i>	<i>1</i>
<i>Particles present</i>	<i>3</i>
<i>Pressure not equalized</i>	<i>2</i>
<i>Wrong dilution volume</i>	<i>1</i>
<i>&lt;6 doses from vial</i>	<i>1</i>
<i>Cold chain</i>	<i>1</i>



# Strengthening Pharmacovigilance and Medicines Support Systems in the Pacific

## COVID 19 Vaccine safety Surveillance

*Associate Professor Michael Tatley*

*University of Otago/New Zealand Pharmacovigilance Centre*

*July 2018*



# The Pacific region

..... Similarities with LMIC...

- Little PV attention/activity in the South Pacific Region

3 countries PV training,  
2 members of PIDM  
21 (2002) & 27 reports

- Huge Area


- Population

11.9 million  
10.13 million (PNG/F/Sol)  
3.37 million (excl. PNG)  
1.77 million (excl. PNG/F/Sol)


- GDP

US\$ 5,923(Avg) US\$ 4,274(Median)

- Historical Affiliations & Independent



# Operational Scenario



# COVID-19 Medication Error

## *Global Epidemiology Questions*

### Coding Schema's?

What coding schema's are being used if any by countries

NZ has developed a Pfizer-specific coding schema to support evaluation of reports

### Collation and review of ME reports from IMSN member countries?

Plans or possibilities to collate/analyze/describe IMSN member countries collective experiences

